Drug intelligence / Profile preview

YSIL6

Development stage: Preclinical
Lead developer: Y's Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

YSIL6 is a small-molecule drug candidate developed for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. It acts as an oral inhibitor of interleukin-6 (IL-6), a cytokine involved in inflammation and immune response. By inhibiting IL-6 signaling, YSIL6 aims to reduce inflammation associated with autoimmune conditions. The drug was initially developed by Y's Therapeutics[1][2][3].

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on YSIL6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YSIL6.

Explore the full profile